ALLMedicine™ Hemophilia A Center

Mar 17th, 2023 - Practice Essentials Acquired hemophilia is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies (inhibitors) directed against plasma coagulation factors, most frequently factor VIII (FVIII). [1] Acq...

Mar 17th, 2023 - Practice Essentials Acquired hemophilia is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies (inhibitors) directed against plasma coagulation factors, most frequently factor VIII (FVIII).[1] Acqu...

Mar 17th, 2023 - Practice Essentials Acquired hemophilia is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies (inhibitors) directed against plasma coagulation factors, most frequently factor VIII (FVIII). [1] Acq...

Mar 16th, 2023 - The National Hemophilia Foundation State of the Science Research Summit initiative sought to unify research efforts in the US inherited bleeding disorders (BDs) community around key topics of importance to people living with inherited BDs, the liv...

Mar 16th, 2023 - Decades of research have transformed hemophilia from severely limiting children's lives to a manageable disorder compatible with a full, active life, for many in high-income countries. The direction of future research will determine whether exciti...

Apr 2nd, 2009 - Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding an...

Mar 14th, 2023 - Participants will receive BIVV001 once weekly for a total of at least 100 exposure days to BIVV001 (including exposure during a BIVV001 parent study, if applicable). Participants will have the opportunity to continue in this study for up to 4 year...

Mar 10th, 2023 - C3731003 is a pivotal Phase 3 study to evaluate the clinical efficacy and safety of a single IV infusion of PF-07055480 / giroctocogene fitelparvovec (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in adult male participants with moderately se...

Mar 10th, 2023 - Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII). FVIII is naturally found in the bl...

Mar 10th, 2023 - People with hemophilia A do not have enough of a protein found naturally in the blood called "clotting factor 8", also known as FVIII. This protein helps the blood to clump together to prevent and stop bleeding. People with lower levels of FVIII o...

Mar 8th, 2023 - This will be a multi-institutional, retrospective review of pediatric patients ages 0 to 36 months of age who are currently receiving and/or have received emicizumab-kxwh as part of their treatment for hemophilia A with or without inhibitors. Part...

Mar 3rd, 2023 - The verbiage surrounding a person's experience with cancer or some other serious illness, particularly references to "battle," has the unintended effect of portraying survivors as "winners" and those who die as "losers." (NPR) The annual cost of n...

Feb 23rd, 2023 - The FDA has approved the recombinant antihemophilic factor Fc-VWF-XTEN fusion protein-ehtl (Altuviiio) for the treatment of adults and children with hemophilia A, Sanofi announced on Thursday. The first-in-class factor VIII replacement therapy car...

Feb 23rd, 2023 - A single infusion of the gene therapy valoctocogene roxaparvovec led to significantly reduced bleeding rates that persisted in men with severe hemophilia A, 2-year results from the phase III GENEr8-1 trial showed. Among 112 men who had been receiv...

Feb 3rd, 2023 - A 19-year-old Iowa woman has been arrested after being accused of faking diagnoses of leukemia and pancreatic cancer in order to collect more than $37,000 in online donations. (CBS News) The Ovarian Cancer Research Alliance is urging even women wi...

Jan 25th, 2023 - Treatment with investigational efanesoctocog alfa (formerly BIVV001) -- a new class of factor VIII replacement therapy -- prevented bleeding episodes in patients with severe hemophilia A, according to results from the phase III XTEND-1 trial. Amon...